Partial
Mostly Misaligned
Patient Risk:
Moderate
Summary
Some claims match label concepts (indications, oral/IV formulations, PR-interval/cardiac rhythm effects). However, several safety claims about increased heart rate/blood pressure frequency, rarity, dose-dependence, and a specific case dechallenge/rechallenge narrative are not supported by the provided label excerpts, and the mechanism/blocking-sodium-channels explanation is not supported as stated.
Category Scores
Accurate Statements
Lacosamide is used to treat epilepsy.
Supported by label indication for treatment of partial-onset seizures in patients ≥1 month and adjunctive therapy for primary generalized tonic-clonic seizures in patients ≥4 years (Section 1.1, 1.2).
Lacosamide is available in oral and injectable forms.
Supported by provided label excerpt listing tablets, oral solution, and injection (IV) (sections 2.6 and 2.7).
Lacosamide can cause increased heart rate.
Partially supported via cardiac rhythm/conduction abnormalities including bradycardia, AV block, and ventricular tachyarrhythmia (Section 2.7 and 5.3), but the specific wording 'increased heart rate' is not directly supported by the provided excerpts.
Lacosamide works by modulating the activity of sodium channels in the nervous system.
Not supported by the provided excerpts; however, the claim is directionally plausible within 'pharmacodynamics' context is not shown in excerpts. No direct label excerpt for sodium-channel mechanism was provided.
Lacosamide is used to treat neuropathic pain.
No label support in provided excerpts (Sections 1.1/1.2 only describe seizure indications).
Unsupported Statements
Lacosamide is used to treat neuropathic pain.
Not supported by provided FDA label excerpts; only seizure indications are shown (Sections 1.1 and 1.2).
Lacosamide works by modulating the activity of sodium channels in the nervous system.
No specific mechanism statement involving sodium channels was included in the provided excerpts.
Lacosamide helps to reduce the frequency and severity of seizures by blocking sodium channels.
No provided excerpt states seizures are reduced by 'blocking sodium channels' and no detailed mechanism excerpt was provided.
Lacosamide can cause increased heart rate.
Provided excerpts mention bradycardia and conduction abnormalities, but do not support 'increased heart rate' specifically.
Lacosamide can cause increased blood pressure.
No provided excerpt reports increased blood pressure as an adverse reaction or warning/precaution.
The FDA has reports of increased blood pressure in patients taking lacosamide.
No provided label excerpt mentions FDA reports or increased blood pressure.
Reports of increased blood pressure from lacosamide are rare.
No provided label excerpt provides frequency/rarity for increased blood pressure.
Reports of increased blood pressure from lacosamide typically occur in patients taking high doses of the medication.
No provided label excerpt ties increased blood pressure to high doses.
There have been case reports of lacosamide causing hypertension.
No provided label excerpt mentions case reports of hypertension.
A case report described a patient taking lacosamide for epilepsy who experienced a significant increase in blood pressure.
No provided label excerpt contains a specific case report narrative.
In the reported case, the blood pressure increase was reversed when the patient stopped taking lacosamide.
No provided label excerpt contains a dechallenge narrative.
Patients taking lacosamide should be monitored for signs of increased blood pressure.
No provided label excerpt includes monitoring specifically for increased blood pressure.
Contradictions
Low
AI Statement
Lacosamide can cause increased heart rate.
Label Reference
Provided excerpts for IV administration/warnings include bradycardia as a cardiac adverse effect (Sections 2.7 and 5.3).
Important Omissions
No label-supported distinction was provided for which lacosamide formulation (tablets/oral solution vs injection) is being referenced when making cardiac monitoring claims.
Importance:
Low
No label-supported cardiovascular monitoring language (e.g., ECG/PR-interval) is referenced; claims were instead directed to 'increased blood pressure' monitoring without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about increased blood pressure/hypertension and monitoring could mislead safety assessment. Some cardiac effects are label-supported but the specific direction ('increased heart rate') and blood-pressure content are not supported by provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Several claims (neuropathic pain indication; blood pressure/hypertension incidence, rarity, dose pattern, case reports, dechallenge reversal; sodium-channel blocking mechanism; and monitoring for increased blood pressure) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to the provided label excerpts: epilepsy indications for partial-onset and adjunctive primary generalized tonic-clonic seizures; formulation availability (tablets/oral solution/injection); and label-supported cardiac warnings (PR-interval prolongation, bradycardia/AV block/ventricular tachyarrhythmia with IV and caution with conduction abnormalities). Remove blood-pressure/case-report narratives and avoid specifying unprovided mechanism details.